ideasIdea

Cancer interception vaccines for high-risk carriers

Vaccinate people with BRCA or Lynch mutations against the antigens their future cancers will express, before any cancer exists.

Lynch syndrome tumours share frameshift neoantigens; BRCA1 tumours are basal-like with predictable antigens. Nous-209 (Lynch) and alpha-lactalbumin vaccine (TNBC, Cleveland Clinic) are in early trials.

Confidence

15%–35%likelyOnCo editors (initial estimate), 2026-09-07 · Long trials with incidence endpoints; biologically attractive.

Hypothesis

Vaccination of Lynch carriers against recurrent frameshift peptides reduces adenoma and cancer incidence over 5 years.

Rationale

Immune system is intact, tumour burden zero, antigens predictable; prevention needs only modest efficacy to be cost-effective.

What would test it

Randomised placebo-controlled trial in Lynch carriers with colonoscopic adenoma incidence endpoint.

Maturity

early clinical

Key papers

1top

translationalClinical Cancer Research 2020

First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers

Because Lynch syndrome tumours make the same abnormal proteins in almost every patient, a single vaccine could in principle be given to carriers before cancer develops. This small trial showed the concept is safe and immunogenic; whether it prevents cancer requires the randomised trials now being planned.

Connected

11top

Pages like this

not linked directly; found by shared links

Cancer interception vaccines for high-risk carriers

Key papers

Connected

Pages like this

cancers

technologies

targets

ideas

bottlenecks

key papers